CABIO(SH:688089) Xin Lang Cai Jing·2025-08-20 08:30Group 1 - The company reported a significant increase in performance for H1 2025, with revenue reaching 307 million yuan, a year-on-year growth of 17.6%, and net profit attributable to shareholders increasing by 59.0% and 88.5% for the non-deduction and deduction cases respectively [1] - In Q2 2025, revenue was 151 million yuan, showing a year-on-year increase of 4.8%, while net profit attributable to shareholders was 63 million yuan and 59 million yuan, reflecting year-on-year growth of 44.5% and 71.4% respectively [1] - The company maintains its profit forecasts for 2025-2027, predicting net profits of 192 million, 230 million, and 276 million yuan, with corresponding EPS of 1.14, 1.37, and 1.64 yuan, indicating a PE ratio of 24.8, 20.7, and 17.2 times [1] Group 2 - The domestic market continues to benefit from the new national standards, driving growth in ARA and DHA, with expectations for continued revenue growth in H2 2025 [2] - The gross profit margin has significantly improved, with a year-on-year increase of 7.24 percentage points and a quarter-on-quarter increase of 1.87 percentage points, attributed to scale effects and reduced costs [2] - The net profit margin for Q2 2025 reached 41.76%, with a year-on-year increase of 11.46 percentage points, indicating strong profitability [2] Group 3 - The restructuring target, Ouyi Biological, has committed to a cumulative net profit of no less than 270 million yuan from 2025 to 2027, averaging 90 million yuan per year, indicating high growth potential [3] - Ouyi Biological is in the early stages of multi-omics analysis, with significant opportunities for overseas market expansion and technological application [3] - The completion of the asset restructuring is expected to enhance the company's foundational R&D capabilities and accelerate new product development [3]